Time to progression · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy
Gemcitabine may leads to lower time to progression compared with BCG (low certainty).
1 finding from 1 review
Adverse events grade 3 to 5 Range of · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy
It is very uncertain whether gemcitabine changes grade III–V adverse events compared with BCG (very low certainty).
1 finding from 1 review
Time to death from bladder cancer · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy
It is very uncertain whether gemcitabine changes time to death from bladder cancer compared with BCG (very low certainty).
1 finding from 1 review
Time to death from any cause · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: grade 1 to 2 · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy
It is very uncertain whether gemcitabine changes grade I or II adverse events compared with BCG (very low certainty).
1 finding from 1 review
Disease‐specific quality of life · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 · adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participant preference · adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exercise tolerance (modified shuttle test) · adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospital admissions · adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Need for extra treatment · adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Systolic blood pressure · people with CKD
1 finding from 1 review
Diastolic blood pressure · people with CKD
1 finding from 1 review
Albuminuria · people with CKD
1 finding from 1 review
Extracellular fluid volume · people with CKD
1 finding from 1 review
Weight (kg) · people with CKD
1 finding from 1 review
Reduction in antihypertensive dose · people with CKD
It is very uncertain whether lower salt intake changes reduction in antihypertensive dose compared with higher salt intake (very low certainty).
1 finding from 1 review
Symptomatic hypotension · people with CKD
Lower salt intake probably leads to higher symptomatic hypotension compared with higher salt intake (moderate certainty).
1 finding from 1 review